BREXIT – Impact on Medical Devices placed in the UK market
From 31 of December 2020, the UK will be regarded as a third country and not a Member State of the European Union. There will be some changes regarding medical devices placed in the UK. The UK’s MHRA has published guidance regarding the regulation of medical devices from 1 January 2021, where it explains what changes and what there is to know about placing a medical device in the Great Britain, Northern Ireland and EU markets.
Liliana Teles

Liliana Teles

Regulatory Affairs Manager

MEDICAL DEVICES LEGAL FRAMEWORK IN THE EU AND UK

After 31 of December 2020 (end of the so-called ‘transition period’), the United Kingdom (UK) will be considered a third country and not a Member State of the European Union, meaning that all EU rules and regulations will no longer be applied to medical devices placed in the UK market. After the transition period, the rules for Northern Ireland will be different from those in Great Britain, as EU rules will continue to apply in this country (e.g. CE marking, EU-based manufacturer or Authorized Representative).

At the moment, medical devices are regulated under Directive 90/385/EEC (on active implantable medical devices – EU AIMDD), Directive 93/42/EEC (on medical devices – EU MDD) and Directive 98/79/EC (on in vitro diagnostic medical devices – EU IVDD), which are given effect in the UK law through the Medical Devices Regulations 2002 (SI 2002 No 618, as amended) (UK MDR 2002). These Regulations (in the form in which they will exist on January 1st 2021) will continue to have effect in Great Britain after the transition period.

In 2017, two Regulations on medical devices and in in vitro diagnostic medical devices entered into force in the European Union (EU) and started to replace the three existing Directives, establishing a modernized and more robust EU legislative framework and safeguarding a better public health protection and patient safety. The EU Medical Devices Regulation (MDR – Regulation (EU) 2017/745) and the In Vitro Diagnostic Medical Devices Regulation (IVDR – Regulation (EU) 2017/746) will fully apply from 26 May 2021 and 26 May 2022, respectively. As these regulations will not take effect until after the transition period with the EU has ended, they will not be EU law automatically retained by the EU Withdrawal Agreement Act and will therefore not automatically apply in Great Britain.

After the transition period, medical devices manufactured in the United Kingdom and placed on the EU market will be regarded as products imported form a third country. In this sense, manufacturers from the UK will need an Authorized Representative and importer located in the European Union. On the other hand, if a manufacture is based outside the UK and wishes to place a medical device on the UK market, it will need to establish an UK Responsible person, who will take the responsibility for the device in this country.

CHANGES FOR MEDICAL DEVICES PLACED IN THE UK

For medical devices placed in Great Britain, there will be some changes, beginning on January 1st 2021.  From this date, the Medicines and Healthcare products Regulatory Agency (MHRA) will be the sole authority responsible for medical devices marketed in the UK. MHRA is the designated competent authority that administers and enforces law on medical devices in the UK.

  • CE Certificates issued by European Economic Area (EEA)-based Notified Bodies will continue to be valid for the Great Britain market until June 30th, 2023.
  • A new route to market and product marking will be available for manufacturers wishing to place a device on the Great Britain market from January 1st 2021.
  • From January 1st 2021, all medical devices and in vitro diagnostic medical devices placed on the UK market will need to be registered with the MHRA. Grace periods will be granted for the registration:
    • 4 months for Class IIIs and Class IIb implantables, and all active implantable medical devices.
    • 8 months for other Class IIb and all Class IIa devices.
    • 12 months for Class I devices (do not apply to manufacturers of Class I devices and general IVDs that are currently required to register with the MHRA).
  • The need for an UK Responsible Person if the manufacture is based outside this country and this manufacture will first need to register with the MHRA.

From 1st January 2021, all medical devices, IVD or custom-made devices need to be registered with MHRA, before being placed on the UK market.

Notified Bodies on the UK will no longer be able to issue CE Mark certificates. The UK Conformity Assessed (UKCA) mark is a new UK product marking that will be applied to medical devices (and other products) being placed in the UK after the transition period. From 1st July 2023, the medical device being marketed in the UK will need to fulfil the requirements for placing the UKCA mark. This UKCA mark will not be recognized in the EU, EEA or Northern Ireland markets and products which are required to have a CE marking will continue to have this requirement to be sold in these markets.

Finally, manufacturers will be required to submit vigilance reports to the MHRA if the medical device is placed in the UK when certain incidents with their device occur in this country.  

References:

  1. Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community, 19 October 2019. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/840655
  2. Medicines and Healthcare products Regulatory Agency (MHRA) – Guidance – Regulating medical devices from 1 January 2021. Available at: https://www.gov.uk/guidance/regulating-medical-devices-from-1-january-2021#contents
  3. Medicines and Healthcare products Regulatory Agency (MHRA) – Medical devices: the regulations and how we enforce them. Available at: https://www.gov.uk/government/publications/report-a-non-compliant-medical-device-enforcement-process/how-mhra-ensures-the-safety-and-quality-of-medical-devices

further
reading

cosmetic products

New Formaldehyde Threshold in Cosmetic Products

The European Commission has issued a draft regulation to amend the preamble of Annex V regarding the threshold for labelling formaldehyde releasers. This amendment results from a scientific advice published by the SCCS concluding that the current threshold does not sufficiently protect consumers sensitized to formaldehyde.

Read More »
cosmetic products

New Restriction on the Use of Benzophenone-3 in Cosmetics

Benzophenone-3 was part of a priority list of potential endocrine disruptors established by the European Commission in 2019. The SCCS was asked to assess the safety of this ingredient and the European Cosmetics Regulation will be amended in accordance with the SCCS assessment conclusions.

Read More »
endocrine disruptors
cosmetic products

European Commission Calls for Data on Ingredients with Potential Endocrine-Disrupting Properties

Substances classified as endocrine disruptors are compounds that can alter the functioning of the endocrine system and negatively affect the health of humans and animals. In 2019, the European Commission set out two lists of ingredients suspected of having endocrine disrupting properties. More recently, the Commission has published a call for data for 10 ingredients that were included in the low priority group (Group B) for the SCCS to be able to assess their safety.

Read More »
cosmetic products

SCCS Preliminary Opinion on Prostaglandins and Prostaglandin-analogues

Following the mandate from the European Commission, the Scientific Committee on Consumer Safety (SCCS) has published a preliminary opinion on Prostaglandins and Prostaglandin-analogues used in cosmetic products. This preliminary opinion is open for comments and the deadline was set for 23 november 2021.

Read More »
cosmetic products

SCCS Preliminary Opinion on Butylated Hydroxytoluene (BHT)

Following the mandate from the European Commission, the Scientific Committee on Consumer Safety (SCCS) has published a preliminary opinion on Butylated Hydroxytoluene (BHT). This preliminary opinion is open for comments and the deadline was set for 23 november 2021.

Read More »
cosmetic products

EU Prohibition of Zinc Pyrithione in Cosmetic Products

Zinc Pyrithione has been used for more than 60 years as an anti-dandruff agent in cosmetic products. Last month, the European Commission published the Commission Regulation (EU) 2021/1092, which includes this ingredient in Annex II. From March 2022 onwards, Zinc Pyrithione will be prohibited in cosmetic products.

Read More »
medical devices

EUDAMED Status Update 2021

The development and deployment of EUDAMED is progressing. Following the implementation plan and getting familiar with the information stored in the database’s modules is crucial for economic operators compliance in the EU market.

Read More »
cosmetic products

EU Chemicals Strategy for Sustainability

The Chemicals Strategy for Sustainability (CSS) was recently published by the European Union. The CSS is part of the European Green Deal which aims for a toxic-free environment leading to zero pollution. The initiative proposes a new legislative amend to the EU Cosmetic Products Regulation. Simplification and digitalization of labelling requirements plus review of the definition of nanomaterial are two of the main objectives of the CSS.

Read More »
cosmetic products

Nanotechnology in Sun Care Products

Nanomaterials are increasingly used in cosmetics and personal care products. They are similar to other chemicals/substances, but with specific risks associated to their use. Currently, there are 4 nano-ingredients approved in the European Union for use as UV filters in cosmetic products.

Read More »
cosmetic products

May Butylphenyl Methylpropional be used in Cosmetic Products?

Butylphenyl Methylpropional, also known as Lilial, is a fragrance ingredient that has been used for years in several cosmetic and non-cosmetic products. Nevertheless, some concerns have been expressed regarding the use of this ingredient and its risk to consumers. According to an amendment to the CLP Regulation, the use of Butylphenyl Methylpropional will be prohibited in cosmetic products from 1st March 2022.

Read More »
cosmetic products

How are Cosmetic Products Regulated in the United Arab Emirates?

The United Arab Emirates (UAE) are an emerging market for the beauty industry. Cosmetics and personal care products supplied or sold in the UAE must comply with the health and safety requirements set out in UAE legislation. Overall, the process for importing a cosmetic product into the UAE market from the European Union can be quite straightforward since the UAE has aligned several of its requirements with the European Cosmetic Regulation.

Read More »